Pharmaceutical Executive-06-01-2011

Emerging Pharma Leaders 2011

FDA's opiod REMS implies there is still value in industry-sponsored CME

The payoff is superior performance in key areas such as clinical trials

NicVAX is trying to buck the trend of smoking-cessation products' high failure rate

Why has the EU still not managed to update its rules on information about medicines?

NeHC's new Consumer Consortium is promoting a new stakeholder agenda to improve patient knowledge

Creating and managing expectations is the most basic rule of marketing

Successful negotiations require a willingness to take risks and an ability to adapt

Patent expiries are inevitable, but brand teams should look to graduate the sales curve

What do our genetics tell us about our predisposition to certain diseases?

A vaccination against addiction could open up a whole new category

To decide on a course of treatment, patients need to be told the truth straight up

The three components of the NicVAX launch challenge

With a first-in-class compound marketers can potentially leverage long-lasting market advantages

Suggestions for testing new ways of addressing difficult issues of risk